Evercore ISI Group Maintains Outperform on Medline, Lowers Price Target to $39

Benzinga · 1d ago
Evercore ISI Group analyst Elizabeth Anderson maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $39.